Kiniksa Pharmaceuticals International, plc
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — | — | — |
| Cost of Revenue | $77.7M | $60.9M | $33.4M | $22.9M | $9.1M | — | — | — |
| Gross Profit | $599.9M | $362.3M | $236.9M | $197.3M | $29.4M | — | — | — |
| Gross Margin | 88.5% | 85.6% | 87.6% | 89.6% | 76.4% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M | $112.0M | $135.0M | $86.6M |
| SG&A Expense | $196.3M | $168.0M | $129.4M | $98.0M | $85.9M | $45.3M | $35.0M | $21.6M |
| Operating Income | $77.2M | $-45.6M | $-25.2M | $9.8M | $-156.6M | $-157.4M | $-170.0M | $-108.2M |
| Operating Margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $88.9M | $-36.2M | $-16.7M | $11.0M | $-156.5M | $-156.2M | $-163.9M | $-103.4M |
| Income Tax Expense | $29.9M | $7.0M | $-30.7M | $-172.3M | $1.4M | $5.2M | $-2.0M | $-214.0K |
| Net Income | $59.0M | $-43.2M | $14.1M | $183.4M | $-157.9M | $-161.4M | $-161.9M | $-103.2M |
| Net Margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | — | — | — |
| EPS (Basic) | $0.80 | $-0.60 | $0.20 | $2.64 | $-2.30 | $-2.61 | $-2.99 | $-3.49 |
| EPS (Diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | $-3.49 |
| Shares Outstanding (Basic) | 74.2M | 71.4M | 70.1M | 69.4M | 68.6M | 61.8M | 54.0M | — |
| Shares Outstanding (Diluted) | 79.0M | 71.4M | 71.9M | 70.4M | 68.6M | 61.8M | 54.0M | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |